CMC & ManufacturingLast reviewed May 2026

EU GMP Annex 11(Annex 11)

The EU GMP annex establishing requirements for computerized systems used in GMP-regulated activities.

Usage Examples

The LIMS validation package was designed to meet both 21 CFR Part 11 and Annex 11 requirements.
Annex 11 audit trail review was integrated into monthly quality reviews.
An EU GMP inspection identified Annex 11 gaps in supplier oversight of the eBMR system.

What is Annex 11?

EU GMP Annex 11 is the European Medicines Agency's regulatory framework for computerized systems used in GMP-regulated activities. It sets expectations for risk-based validation, supplier management, user management, audit trails, electronic signatures, data integrity, periodic review, and incident management across computerized systems — from manufacturing execution systems (MES) to laboratory information management systems (LIMS) and electronic batch records.

Annex 11 is the EU counterpart to FDA 21 CFR Part 11, but with some differences. Part 11 focuses primarily on electronic records and electronic signatures as legal equivalents of paper-based records and handwritten signatures. Annex 11 has broader scope covering the full lifecycle of computerized systems, risk-based validation, supplier oversight, and a more explicit expectation of periodic review and risk reassessment. Most global pharmaceutical companies operate a combined Part 11/Annex 11 compliance framework.

Annex 11 non-compliance is cited in EU GMP inspections and can affect Qualified Person (QP) release decisions, EU regulatory approvals, and commercial supply. Audit trail review completeness, system validation documentation, and data integrity controls are the most frequently cited Annex 11 deficiencies during inspections.

Regulatory Context

This term appears most often in cmc & manufacturing workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside EUDRALEX VOLUME 4 ANNEX 11, EU GMP.

FDAICHHealth Canada

When This Matters

The LIMS validation package was designed to meet both 21 CFR Part 11 and Annex 11 requirements.
Annex 11 audit trail review was integrated into monthly quality reviews.
An EU GMP inspection identified Annex 11 gaps in supplier oversight of the eBMR system.

Common Mistakes

Failing to align CMC change narratives with current CFR/ICH expectations.
Submitting incomplete control strategy documentation.
Separating manufacturing and regulatory review cycles too late in execution.

Related Regulations

EUDRALEX VOLUME 4 ANNEX 11EU GMP

Frequently Asked Questions

Part 11 (FDA) focuses on electronic records and electronic signatures as legal equivalents of paper. Annex 11 (EU) has broader scope: risk-based validation, supplier management, user management, audit trails, data integrity, and periodic review across the full computerized system lifecycle. Most global companies meet both through a unified compliance framework.

Annex 11 applies to GMP-regulated computerized systems. Computerized systems supporting Phase 1 IMP manufacture have proportionate expectations; Phase 2/3 and commercial systems require full Annex 11 compliance. Annex 13 of EU GMP covers IMP manufacturing and interacts with Annex 11 expectations.

The Qualified Person (QP) is legally responsible for certifying each EU batch for release. That certification depends on data integrity and validated computerized systems — QPs cannot release batches based on unreliable or uncontrolled system outputs. Annex 11 failures directly affect QP release decisions and EU commercial supply.